Abstract:BACKGROUND:The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.OBJECTIVE:To investigate the actions of the renin-angiotensin system in vascular protection mediated by activation of PPARγ in vivo and in vitro.METHODS:Rats were fed a regular diet (n = 8), a cholesterol-rich diet plus methylthiouracil (80 mg/Kg/day, n = 10), a cholesterol-rich diet plus methylthiouracil and rosiglitazone (4 mg/kg/day, n = 10). The rosiglitazone treatment was started from one month after the start of cholesterol-rich diet plus methylthiouracil, and lasted five months. Cultured vascular smooth muscle cells (VSMCs) were pretreated with 1 μmol/L angiotensin II (ANG II) for 6 h and randomly divided into the control group; the ANG II group (1 μmol/L ANG II); the groups respectively treated with different concentration rosiglitazone (20, 30, 50) μmol/L for 12 h; the groups treated with 30 μmol/L rosiglitazone for (6, 12, 24) h. Morphology changes of the aortic tissues were observed by hematoxylin and eosin stain. The VSMC growth was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Angiotensin II and expression of angiotensin receptors were determined by radioimmunoassay, reverse transcription polymerase chain reaction (RT-PCR), western blot, and immunohistochemistry.RESULTS:After 6 months, lipid deposition, VSMC proliferation and migration toward intima were observed in aortic tissues in the rats on a cholesterol-rich diet plus methylthiouracil, while these pathological changes induced by the cholesterol-rich diet were significantly suppressed by rosiglitazone. In addition, VSMC proliferation induced by ANG II was markedly inhibited by rosiglitazone. Rosiglitazone markedly down-regulated expression of angiotensin type 1 receptor (AT1R) and up-regulated expression of angiotensin type 2 receptor (AT2R) in the aortic tissues and ANG II-treated VSMCs.CONCLUSIONS:The present study demonstrated that PPARγ agonist rosiglitazone suppressed ANG II-induced VSMC proliferation in vitro and early atherosclerotic formation evoked by cholesterol-rich diet in vivo. These vasculoprotective effects of rosiglitazone were mediated at least partially by reduction in local tissue ANG II concentration, down-regulation of AT1R expression and up-regulation of AT2R expression both at the mRNA and protein levels.

Inhibitory effects of rosiglitazone and ciglitazone on rat aortic adventitial fibroblasts proliferation induced by angiotensin Ⅱ in vitro

Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ

Rosiglitazone ameliorates the dysfunction of endothelial progenitor cells induced by advanced glycation end products

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

Effects of Rosiglitazone on Proliferation of Vascular Smooth Muscle Cells Induced by Angiotensin Ⅱ

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

Effects of Rosiglitazone on the Expression of Angiotensin Ⅱ Type 1 Receptor and Type 2 Receptor in Angiotensin Ⅱ-Induced Mice Vascular Smooth Muscle Cells

Rosiglitazone Inhibitory Effect on Mesangial Cell Proliferation and Extracellular Matrix Expression Induced by Angiotensin Ⅱ

Effects of combination of pioglitazone and rosuvastatin on rat adventitial fibroblasts oxidization and inflammation induced by Ang Ⅱ

Rosiglitazone Inhibits Angiotensin II-induced CTGF Expression in Vascular Smooth Muscle Cells––role of PPAR-γ in Vascular Fibrosis

Inhibition of Rosiglitazone on the Proliferation, Connective Tissue Growth Factor and Smad Expression in Cultured Cardiac Fibroblasts Induced by Advanced Glycosylation End-Products

Effects of rosiglitazone on expression of angiotensinⅡtype 2 receptor in angiotensinⅡ-induced rat vascular smooth muscle cells

Rosiglitzone Suppresses Angiotensin II-Induced Production of KLF5 and Cell Proliferation in Rat Vascular Smooth Muscle Cells

Effect of Rosiglitazone on the Proliferation and NO Secretion of Cultured Cardiac Fibroblasts Induced by AGEs

Effect of rosiglitazone on cardiac fibroblast proliferation, nitric oxide production and connective tissue growth factor expression induced by advanced glycation end-products.

Protective Effects of Rosiglitazone on Non-Alcoholic Steatohepatitis in Rats

[Inhibitory Effects of Rosiglitazone Against Endothelin-1-induced Proliferation of Rat Cardiac Myocytes: the Role of PKC-c-fos Pathway].

Inhibitory Effects of Rosiglitazone on the Expression of Transforming Growth Factor-β_1 in Rat Mesangial Cells Cultured in High Glucose

Vasculoprotective Effects of Rosiglitazone Through Modulating Renin-Angiotensin System in Vivo and Vitro.

The Effect of Rosiglitazone in Modulating Cyclooxygenases-2 in Nonalcoholic Steatohepatitis Rats

Effects of pioglitazone on angiotensin Ⅱ-induced proliferation and collagen expression of adventitial fibroblasts